DE1227615B - Verfahren zur Herstellung stabiler Impfstoffpraeparate - Google Patents
Verfahren zur Herstellung stabiler ImpfstoffpraeparateInfo
- Publication number
- DE1227615B DE1227615B DEP32328A DEP0032328A DE1227615B DE 1227615 B DE1227615 B DE 1227615B DE P32328 A DEP32328 A DE P32328A DE P0032328 A DEP0032328 A DE P0032328A DE 1227615 B DE1227615 B DE 1227615B
- Authority
- DE
- Germany
- Prior art keywords
- vaccine
- solution
- virus
- drying
- solutions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 title claims description 44
- 238000000034 method Methods 0.000 title claims description 10
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title claims description 5
- 239000002970 Calcium lactobionate Substances 0.000 claims description 24
- 235000019307 calcium lactobionate Nutrition 0.000 claims description 24
- 229940050954 calcium lactobionate Drugs 0.000 claims description 24
- RHEMCSSAABKPLI-SQCCMBKESA-L calcium;(2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanoate Chemical compound [Ca+2].[O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O.[O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RHEMCSSAABKPLI-SQCCMBKESA-L 0.000 claims description 24
- 241000700605 Viruses Species 0.000 claims description 21
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- 238000004108 freeze drying Methods 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 description 64
- 238000001035 drying Methods 0.000 description 22
- 238000011081 inoculation Methods 0.000 description 21
- 239000000047 product Substances 0.000 description 18
- 230000000890 antigenic effect Effects 0.000 description 13
- 239000012520 frozen sample Substances 0.000 description 12
- 238000003860 storage Methods 0.000 description 12
- 239000013068 control sample Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000007710 freezing Methods 0.000 description 10
- 230000008014 freezing Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 102000008100 Human Serum Albumin Human genes 0.000 description 9
- 108091006905 Human Serum Albumin Proteins 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 230000000087 stabilizing effect Effects 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000003381 stabilizer Substances 0.000 description 8
- 102000009027 Albumins Human genes 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229940041323 measles vaccine Drugs 0.000 description 7
- 208000000474 Poliomyelitis Diseases 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 238000010257 thawing Methods 0.000 description 5
- 241000700626 Cowpox virus Species 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 201000005505 Measles Diseases 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000000859 sublimation Methods 0.000 description 3
- 230000008022 sublimation Effects 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 241000711386 Mumps virus Species 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002070 germicidal effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940099584 lactobionate Drugs 0.000 description 2
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 2
- 239000012263 liquid product Substances 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US217293A US3186908A (en) | 1962-08-16 | 1962-08-16 | Calcium lactobionate stabilization of labile antigenic virus vaccine materials |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1227615B true DE1227615B (de) | 1966-10-27 |
Family
ID=22810442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DEP32328A Pending DE1227615B (de) | 1962-08-16 | 1963-08-01 | Verfahren zur Herstellung stabiler Impfstoffpraeparate |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US3186908A (en:Method) |
| BR (1) | BR6351350D0 (en:Method) |
| CH (1) | CH412201A (en:Method) |
| DE (1) | DE1227615B (en:Method) |
| DK (1) | DK104193C (en:Method) |
| ES (1) | ES290512A1 (en:Method) |
| FI (1) | FI40108C (en:Method) |
| FR (1) | FR1594506A (en:Method) |
| GB (1) | GB1049386A (en:Method) |
| SE (1) | SE314774B (en:Method) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4380582A (en) * | 1965-07-09 | 1983-04-19 | The United States Of America As Represented By The Secretary Of The Army | Preparation of dry variola virus |
| DE1617457A1 (de) * | 1966-12-16 | 1972-04-20 | Erba Carlo Spa | Verfahren zur Stabilisierung von Zubereitungen interferierender Virusprodukte |
| FR2076787A5 (en) * | 1970-01-28 | 1971-10-15 | Merieux Inst | Lyophilisation stabiliser - for viruses contg potassium phosphate lactose and albumin |
| JPS5716823A (en) * | 1980-07-03 | 1982-01-28 | Green Cross Corp:The | Live mumps vaccine pharmaceutical and stabilizing method |
| FR2505657A1 (fr) * | 1981-05-13 | 1982-11-19 | Pasteur Institut | Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation |
| JPS59163313A (ja) * | 1983-03-09 | 1984-09-14 | Teijin Ltd | 経鼻投与用ペプチドホルモン類組成物 |
| GB0218821D0 (en) * | 2002-08-13 | 2002-09-18 | Glaxosmithkline Biolog Sa | Novel compositions |
| CN116115766B (zh) * | 2023-02-06 | 2024-04-09 | 广东永顺生物制药股份有限公司 | 一种活疫苗耐热冻干保护剂及其制备方法与应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2879202A (en) * | 1954-11-05 | 1959-03-24 | American Cyanamid Co | Stabilization of live viral vaccines by hexahydric alcohols |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA603832A (en) * | 1960-08-23 | J. Scott William | Method and means for the dried storage of micro-organisms | |
| US2186975A (en) * | 1933-04-10 | 1940-01-16 | Horace S Isbell | Crystalline calcium lactobionate calcium bromide and process for making the same |
| GB716920A (en) * | 1951-07-31 | 1954-10-20 | Andre Jean Pierre Joseph Thoma | A process for the mass production and treatment of pathogenic viruses and substances which accompany them |
| US2912361A (en) * | 1956-11-28 | 1959-11-10 | Sterling Drug Inc | Canine distemper vaccine and its preparation |
| US2946724A (en) * | 1957-05-29 | 1960-07-26 | American Cyanamid Co | Stable poliomyelitis live virus vaccine |
| GB899011A (en) * | 1958-03-14 | 1962-06-20 | Upjohn Co | Rubeola vaccine and process |
| US3031378A (en) * | 1959-05-30 | 1962-04-24 | Ishidate Morizo | Method of inactivating viruses |
| GB900115A (en) * | 1960-06-15 | 1962-07-04 | Armour & Co | Improvements in or relating to trypsin solutions |
-
1962
- 1962-08-16 US US217293A patent/US3186908A/en not_active Expired - Lifetime
-
1963
- 1963-08-01 DK DK368963AA patent/DK104193C/da active
- 1963-08-01 DE DEP32328A patent/DE1227615B/de active Pending
- 1963-08-01 BR BR151350/63A patent/BR6351350D0/pt unknown
- 1963-08-01 ES ES290512A patent/ES290512A1/es not_active Expired
- 1963-08-01 GB GB30644/63A patent/GB1049386A/en not_active Expired
- 1963-08-01 SE SE8487/63A patent/SE314774B/xx unknown
- 1963-08-01 FR FR1594506D patent/FR1594506A/fr not_active Expired
- 1963-08-01 CH CH954763A patent/CH412201A/fr unknown
- 1963-08-01 FI FI150063A patent/FI40108C/fi active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2879202A (en) * | 1954-11-05 | 1959-03-24 | American Cyanamid Co | Stabilization of live viral vaccines by hexahydric alcohols |
Also Published As
| Publication number | Publication date |
|---|---|
| CH412201A (fr) | 1966-04-30 |
| FR1594506A (en:Method) | 1970-06-08 |
| ES290512A1 (es) | 1963-11-16 |
| FI40108B (en:Method) | 1968-06-28 |
| GB1049386A (en) | 1966-11-23 |
| US3186908A (en) | 1965-06-01 |
| SE314774B (en:Method) | 1969-09-15 |
| DK104193C (da) | 1966-04-18 |
| FI40108C (fi) | 1968-10-10 |
| BR6351350D0 (pt) | 1973-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69232617T2 (de) | Gefriergetrocknete Zubereitung, die einen monoklonalen Antikörper enthält | |
| DE3932469A1 (de) | Antimikrobielle hydroxyapatit-pulver und verfahren zu ihrer herstellung | |
| DE68915359T3 (de) | Verfahren zur Stabilisierung von Impfstoffen, Assoziationen von attenuierten, lyophilisierten Impfstoffen und erhaltene Zusammensetzungen. | |
| DE2219635B2 (de) | Insulinsalz-Protamin-Komplexe und Verfahren zu ihrer Herstellung | |
| DE2817891A1 (de) | Nd-impfstoff und verfahren zu seiner herstellung | |
| DE1199925B (de) | Verfahren zur Herstellung hochwirksamer Aluminiumoxyd-Depotimpfstoffe | |
| DE1227615B (de) | Verfahren zur Herstellung stabiler Impfstoffpraeparate | |
| DE2463143C2 (de) | Polyvalente Rindervirus-Lebendimpfstoffe | |
| DE69101784T2 (de) | Stabilisierte zusammensetzung enthaltend ein fibroblastwachstumsfaktor. | |
| DE2405675A1 (de) | Verfahren zur inaktivierung von viren und die herstellung von vakzinen | |
| DE1198489B (de) | Verfahren zur Herstellung eines Impfstoffes gegen Panleucopenie | |
| DE1906699A1 (de) | Neue Polymyxinderivate und Verfahren zu deren Herstellung | |
| DE2262427C3 (de) | Immunostimulierendes Mittel | |
| CH423095A (de) | Verfahren zur Herstellung eines Tollwutimpfstoffes | |
| DE2752725C2 (de) | Stabilisierter Poliomyelitis-Impfstoff und Verfahren zu seiner Herstellung | |
| DE2058645C2 (de) | Verfahren zur Herstellung eines stark abgeschwächten Newcastle-Disease-Virus-Lebendimpfstoffs | |
| DE2854723C3 (de) | Hetero-Impfstoff zur therapeutischen Behandlung des Trichomonas -Syndroms und Verfahren zu seiner Herstellung | |
| AT241689B (de) | Verfahren zur Stabilisierung von Virusantigenmaterial | |
| AT88675B (de) | Verfahren zur Herstellung von spezifischen Impfstoffen aus Reinkulturen von Mikroorganismen. | |
| DE2158293B2 (de) | Lebende Herpes-Viren der Gruppe B enthaltende Vaccine und Verfahren zu ihrer Herstellung | |
| DE2165401C3 (de) | Inaktivierter Kombinationsimpfstoff zum Immunisieren von Geflügel gegen Infektion der Atmungsorgane | |
| DE947827C (de) | Verfahren zur Konservierung zersetzlicher Stoffe | |
| DE2213709A1 (de) | Verfahren zur Herstellung eines Interferonerzeugers | |
| DE3009064A1 (de) | Verfahren zur herstellung eines tollwutimpfstoffes und danach erhaltener impfstoff | |
| AT376884B (de) | Verfahren zur inaktivierung von vermehrungsfaehigen krankeitserregern |